Evidence map›Paper›PMID 41164191›Full record

ArticleFrontiers in immunology2025

The utility of CXCL13 and circulating CXCR5

Yu Liu, Si-Yu Tan, Meng-Ke Huang, Yun-Long Yang, Lu Hui, Ting Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu LiuDepartment of Laboratory Medicine, West China Second University Hospital, and West China Hospital, Sichuan University, Chengdu, China.
Si-Yu TanDepartment of Laboratory Medicine, West China Second University Hospital, and West China Hospital, Sichuan University, Chengdu, China.
Meng-Ke HuangDepartment of Laboratory Medicine, West China Second University Hospital, and West China Hospital, Sichuan University, Chengdu, China.
Yun-Long YangDepartment of Laboratory Medicine, West China Second University Hospital, and West China Hospital, Sichuan University, Chengdu, China.
Lu Hui *Department of Clinical Laboratory, Honghui Hospital, Xi'an Jiaotong University, Xi'an, China.
Ting Liu *Department of Laboratory Medicine, West China Second University Hospital, and West China Hospital, Sichuan University, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: CXCL13 regulates the homing of lymphocytes. It is highly expressed in kidney and serum of SLE patients, and correlates with disease activity, but its value in LN is unclear. This study was to investigate the expression and diagnostic value of CXCL13 and its regulated CXCR5 Methods: In mice, the association of serum CXCL13 levels with renal function was analyzed. And CXCR5 Results: CXCL13 was elevated in both mouse and patients, and was positively correlated with disease severity. Serum CXCL13 had an AUC of 0.9287 in the diagnosis of SLE and 0.6244 in differential diagnosis of LN. And in MRL/lpr mice, CXCL13 was involved in the development of nephritis by promoting the recruitment of CXCR5 Discussion: Serum CXCL13 has high accuracy in the diagnosis of SLE, and circulating CXCR5

Indexed as

Chemokine CXCL13Lupus Erythematosus, SystemicLupus NephritisReceptors, CXCR5T-LymphocytesT-Lymphocyte SubsetsAdultAnimalsBiomarkersFemaleHumansKidneyMaleMiceMice, Inbred MRL lprMiddle AgedBiomarkersChemokine CXCL13CXCL13 protein, humanCxcl13 protein, mouseCXCR5 protein, humanReceptors, CXCR5biomarkerCXCL13CXCR5+ T celllupus nephritissystemic lupus erythematosus

Identifiers

PMID41164191
PMCPMC12558933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.